{
    "clinical_study": {
        "@rank": "119607", 
        "arm_group": [
            {
                "arm_group_label": "Arm A (mantle-cell lymphoma)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm B (other B-cell lymphomas)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "Purpose of Phase II study for B-cell lymphoma using PS341: Evaluate efficacy and toxicity of\n      bortezomib in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma."
        }, 
        "brief_title": "Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy", 
        "completion_date": {
            "#text": "March 2005", 
            "@type": "Actual"
        }, 
        "condition": "Lymphoma, B-Cell", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients were stratified, based on preclinical data, into arm A (mantle-cell lymphoma) or\n      arm B (other B-cell lymphomas) without limitation in number of prior therapies. Bortezomib\n      was administered as an intravenous push (1.5 mg/m2) on days 1, 4, 8, and 11 every 21 days\n      for a maximum of six cycles."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION:\n\n          -  Relapsed or Refractory B cell lymphoma.\n\n          -  Zubrod status </= 3.\n\n          -  Measurable disease.\n\n          -  No anti-cancer treatment within past 3 weeks.\n\n          -  ANC >= 1500/uL, Plt >/= 50,000, Bilirubin <2 mg/dL, SGPT <2.5xULN, creatinine <2.\n             Patients with ANC>/1000, PLT>/30000 will be eligible if due to massive splenomegaly\n             and/or BM involvement.\n\n          -  HIV negative.\n\n          -  No active CNS lymphoma.\n\n          -  No serious intercurrent illness, active infections or cancer except basal cell\n             carcinoma of the skin or in situ cervical carcinoma.\n\n          -  Not eligible for treatment of a higher priority. Patients may be entered before BMT.\n\n          -  No pregnancy & age bearing females must be practicing adequate contraception.\n\n          -  Age > 16.\n\n        EXCLUSION:\n\n          -  Patients with platelets <30x10(9)/L within 14 days before enrollment.\n\n          -  Patients with ANC<1.0 x10(9)/L within 14 days before enrollment.\n\n          -  Patients with peripheral neuropathy >/= grade 3 within 14 days before enrollment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "17 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 31, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00038571", 
            "org_study_id": "ID01-596"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A (mantle-cell lymphoma)", 
                "Arm B (other B-cell lymphomas)"
            ], 
            "description": "1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.", 
            "intervention_name": "PS341 (Bortezomib)", 
            "intervention_type": "Drug", 
            "other_name": [
                "Velcade", 
                "LPD-341", 
                "MLN341", 
                "PS-341"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cancer", 
            "Relapsed", 
            "Refractory", 
            "B cell lymphoma", 
            "Proteasome Inhibitor", 
            "PS-341"
        ], 
        "lastchanged_date": "July 27, 2012", 
        "link": {
            "description": "UT MD Anderson Cancer Center website", 
            "url": "http://www.mdanderson.org"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "UT MD Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Proteasome Inhibitor PS-341 For Patients With Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy", 
        "overall_official": {
            "affiliation": "UT MD Anderson Cancer Center", 
            "last_name": "Luis Fayad, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Patient response evaluated according to criteria of Cheson et al.  Endoscopy obtained every two cycles to evaluate response using Complete Response (CR), Partial Response (PR), Progressive Disease, or Stable Disease.", 
            "measure": "Number of Patients with Response to PS-341", 
            "safety_issue": "No", 
            "time_frame": "Every two 21-day cycles"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038571"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "15613697", 
            "citation": "Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F, Rodriguez AM. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005 Feb 1;23(4):667-75. Epub 2004 Dec 21."
        }, 
        "source": "M.D. Anderson Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "M.D. Anderson Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }, 
    "geocoordinates": {
        "UT MD Anderson Cancer Center": "29.76 -95.369"
    }
}